NASDAQ:KNSA • GB00BRXB0C07
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for KINIKSA PHARMACEUTICALS INTE (KNSA).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-25 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-02-25 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2026-02-19 | Canaccord Genuity | Initiate | Buy |
| 2026-01-13 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-10-29 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-10-17 | Citigroup | Maintains | Buy -> Buy |
| 2025-10-13 | Wedbush | Maintains | Outperform -> Outperform |
| 2025-09-29 | TD Cowen | Initiate | Buy |
| 2025-09-25 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-07-29 | Jefferies | Maintains | Buy -> Buy |
| 2025-07-09 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-04-29 | Jefferies | Maintains | Buy -> Buy |
| 2025-04-16 | Wedbush | Reiterate | Outperform -> Outperform |
| 2025-03-13 | Citigroup | Initiate | Buy |
| 2024-11-05 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-10-30 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-09-13 | Jefferies | Initiate | Buy |
| 2024-07-23 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-05-03 | Wells Fargo | Initiate | Overweight |
| 2024-05-01 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-04-24 | Evercore ISI Group | Maintains | Outperform -> Outperform |
| 2024-01-02 | Wedbush | Maintains | Outperform -> Outperform |
| 2023-07-26 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-03-09 | JP Morgan | Maintains | Overweight |
| 2021-12-29 | B of A Securities | Maintains | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 270.259M 22.74% | 423.239M 56.60% | 677.564M 60.09% | 932.36M 37.60% | 1.098B 17.77% | 1.265B 15.21% | 1.382B 9.25% | 1.54B 11.43% | 1.775B 15.26% | 2.033B 14.54% | 2.513B 23.61% | |
| EBITDA YoY % growth | -22.855M -287.75% | -43.921M -92.17% | 78.775M 279.36% | 193.69M 145.88% | 345.05M 78.15% | 423.65M 22.78% | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -25.196M -357.81% | -45.616M -81.04% | 77.221M 269.28% | 133.81M 73.28% | 179.28M 33.98% | 200.9M 12.06% | 301.61M 50.13% | 473.38M 56.95% | 765.59M 61.73% | 1.019B 33.10% | 1.394B 36.80% | |
| Operating Margin | -9.32% | -10.78% | 11.40% | 14.35% | 16.33% | 15.88% | 21.82% | 30.74% | 43.13% | 50.12% | 55.47% | |
| EPS YoY % growth | 0.18 -93.05% | -0.61 -438.89% | 0.74 221.31% | 1.52 105.97% | 2.31 51.54% | 2.40 3.89% | 3.08 28.23% | 4.77 55.03% | 7.58 58.98% | 10.87 43.38% | 17.71 62.85% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 0.22 97.28% | 0.25 8.34% | 0.29 25.44% | 0.37 116.86% | 0.36 64.51% | 0.40 59.65% | 0.42 44.95% | 0.43 16.21% |
| Revenue Q2Q % growth | 211.24M 53.31% | 226.68M 44.57% | 240.58M 33.02% | 253.14M 25.24% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | 24.797M 82.10% | 26.131M 25.25% | 31.879M 26.97% | 51.868M 143.26% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 22.719M 71.18% | 27.345M 35.64% | 32.744M 36.31% | 41.31M 108.97% | N/A | N/A | N/A | N/A |
All data in USD
14 analysts have analysed KNSA and the average price target is 56.97 USD. This implies a price increase of 16.42% is expected in the next year compared to the current price of 48.94.
KINIKSA PHARMACEUTICALS INTE (KNSA) will report earnings on 2026-04-21.
The consensus EPS estimate for the next earnings of KINIKSA PHARMACEUTICALS INTE (KNSA) is 0.22 USD and the consensus revenue estimate is 211.24M USD.
The number of analysts covering KINIKSA PHARMACEUTICALS INTE (KNSA) is 14.